[
  {
    "ts": "2026-01-12T14:05:34+00:00",
    "headline": "Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities reported a strong but volatile performance in the fourth quarter, with the S&P 500 Index returning 2.7% while the benchmark Russell Midcap Growth Index declined 3.7%. In this environment, a […]",
    "url": "https://finance.yahoo.com/news/lifted-vertex-pharmaceuticals-vrtx-q4-140534784.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "52a2440b-63b3-36be-b3f5-e000b4fcde1e",
      "content": {
        "id": "52a2440b-63b3-36be-b3f5-e000b4fcde1e",
        "contentType": "STORY",
        "title": "Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4",
        "description": "",
        "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities reported a strong but volatile performance in the fourth quarter, with the S&P 500 Index returning 2.7% while the benchmark Russell Midcap Growth Index declined 3.7%. In this environment, a […]",
        "pubDate": "2026-01-12T14:05:34Z",
        "displayTime": "2026-01-12T14:05:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/73o67FZt31QGX4RW9oCwEA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eKC281F2zJCXGmB_sO5saA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lifted-vertex-pharmaceuticals-vrtx-q4-140534784.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lifted-vertex-pharmaceuticals-vrtx-q4-140534784.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T11:24:00+00:00",
    "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
    "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
    "url": "https://www.biopharmadive.com/news/abbvie-buys-into-pd-1vegf-sweepstakes-alnylam-and-vertex-set-expectations/809312/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "0bde043c-d553-3ccd-bf4d-18cae76c848c",
      "content": {
        "id": "0bde043c-d553-3ccd-bf4d-18cae76c848c",
        "contentType": "STORY",
        "title": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
        "description": "",
        "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
        "pubDate": "2026-01-12T11:24:00Z",
        "displayTime": "2026-01-12T11:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/abbvie-buys-into-pd-1vegf-sweepstakes-alnylam-and-vertex-set-expectations/809312/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-buys-pd-1-vegf-112400265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BEAM"
            },
            {
              "symbol": "ATRA"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  }
]